Casdin Partners Master Fund, L Buys 225,000 Shares of Standard BioTools (NASDAQ:LAB) Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L bought 225,000 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were acquired at an average price of $1.12 per share, for a total transaction of $252,000.00. Following the completion of the transaction, the director owned 61,100,000 shares in the company, valued at $68,432,000. This represents a 0.37% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Wednesday, November 12th, Casdin Partners Master Fund, L purchased 375,000 shares of Standard BioTools stock. The shares were acquired at an average price of $1.19 per share, with a total value of $446,250.00.
• On Tuesday, November 11th, Casdin Partners Master Fund, L acquired 300,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.20 per share, for a total transaction of $360,000.00.
• On Monday, November 10th, Casdin Partners Master Fund, L acquired 275,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.17 per share, for a total transaction of $321,750.00.
• On Tuesday, September 9th, Casdin Partners Master Fund, L bought 100,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.29 per share, with a total value of $129,000.00.
• On Wednesday, September 3rd, Casdin Partners Master Fund, L purchased 250,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.27 per share, for a total transaction of $317,500.00.
• On Tuesday, August 26th, Casdin Partners Master Fund, L purchased 125,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.26 per share, for a total transaction of $157,500.00.
• On Monday, August 25th, Casdin Partners Master Fund, L acquired 200,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.24 per share, with a total value of $248,000.00.
• On Friday, August 22nd, Casdin Partners Master Fund, L acquired 200,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.26 per share, with a total value of $252,000.00.
• On Friday, August 15th, Casdin Partners Master Fund, L bought 150,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.22 per share, for a total transaction of $183,000.00.
• On Thursday, August 14th, Casdin Partners Master Fund, L bought 133,220 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.21 per share, for a total transaction of $161,196.20.

Standard BioTools Stock Up 1.7%

Shares of LAB stock opened at $1.20 on Friday. The company has a market capitalization of $461.48 million, a P/E ratio of -3.75 and a beta of 1.25. Standard BioTools Inc. has a 12-month low of $0.92 and a 12-month high of $2.25. The firm has a 50-day moving average price of $1.29 and a 200 day moving average price of $1.23.

Analysts Set New Price Targets

A number of research firms have recently issued reports on LAB. Weiss Ratings reiterated a “sell (d-)” rating on shares of Standard BioTools in a research note on Wednesday, October 8th. Wall Street Zen downgraded Standard BioTools from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 8th. TD Cowen reduced their price objective on Standard BioTools from $1.55 to $1.35 and set a “hold” rating on the stock in a research note on Wednesday, November 5th. Finally, Cowen lowered Standard BioTools from a “buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Standard BioTools has a consensus rating of “Reduce” and a consensus target price of $1.35.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of LAB. Vanguard Group Inc. raised its stake in shares of Standard BioTools by 1.6% during the third quarter. Vanguard Group Inc. now owns 17,245,583 shares of the company’s stock worth $22,419,000 after buying an additional 263,845 shares during the last quarter. Geode Capital Management LLC grew its holdings in Standard BioTools by 3.3% during the 2nd quarter. Geode Capital Management LLC now owns 7,441,134 shares of the company’s stock worth $8,931,000 after acquiring an additional 235,677 shares during the period. Long Focus Capital Management LLC acquired a new stake in Standard BioTools during the 1st quarter worth $7,236,000. ARK Investment Management LLC raised its position in shares of Standard BioTools by 3.9% during the 1st quarter. ARK Investment Management LLC now owns 3,452,890 shares of the company’s stock valued at $3,729,000 after acquiring an additional 129,201 shares during the last quarter. Finally, Mirabella Financial Services LLP lifted its stake in shares of Standard BioTools by 5.0% in the 2nd quarter. Mirabella Financial Services LLP now owns 3,434,387 shares of the company’s stock valued at $4,121,000 after purchasing an additional 163,714 shares during the period. Institutional investors own 53.74% of the company’s stock.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.